Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CAD | P27708 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2026408 | 0.81 | MGAM (0.34) | MGAMGAASIMGAM2LMNA | |
| SCHEMBL2024057 | 0.79 | GABRP (0.34) | MGAMGAASIMGAM2LMNA | |
| SCHEMBL10831764 | 0.77 | — | — | |
| SCHEMBL9135825 | 0.76 | TGFBR1 (0.42) | MMP1MGAMGAASIMGAM2 | |
| SCHEMBL4440551 | 0.75 | POLB (0.40) | MMP1ALDH1A1CYP2D6CYP2C19SMN1; SMN2 | |
| Dimethylamine SCHEMBL28561741 | 0.74 | MGAM (0.36) | MGAMGAASIMGAM2LMNA | |
| SCHEMBL28719441 | 0.72 | CYP2D6 (0.41) | MMP1GAAALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL14842010 | 0.72 | MMP1 (0.30) | MMP1 | |
| SCHEMBL8802055 | 0.72 | LMNA (0.41) | MMP1LMNATHRB | |
| SCHEMBL6729274 | 0.70 | ALDH1A1 (0.45) | MMP1ALDH1A1CYP2D6CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427451-B1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CO LTD (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2018-10-25 | — | — | US | disclosed |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-9682996-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-20160215007-A1 | METHOD OF PRODUCING PYRAZINO[2,1-C][1,2,4]TRIAZINE COMPOUND | PRISM PHARMA CO., LTD. (JP) | 2016-07-28 | — | — | US | disclosed |
| EP-3045464-A1 | METHOD OF PRODUCING PYRAZINO[2,1-C][1,2,4]TRIAZINE COMPOUND | PRISM Pharma Co., Ltd. (JP) | 2016-07-20 | — | — | EP | disclosed |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | Prism BioLab Co., Ltd. (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-9193734-B2 | Alpha helix mimetics and methods relating thereto | PRISM PHARMA CO., LTD. (JP) | 2015-11-24 | — | — | US | disclosed |
| US-9126981-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-8455488-B2 | Alpha helix mimetics and methods relating thereto | PRISM BIOLAB CORPORATION (JP) | 2013-06-04 | — | — | US | disclosed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
| EP-2427451-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BioLab Corporation (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20110263607-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BIOLAB CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2346871-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BioLab Corporation (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20110092459-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2303887-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism Biolab Corporation (JP) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010128685-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010044485-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BIOLAB CORPORATION (JP) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009148192-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | MMP1 914/4885MGAM 4301/4885GAA 367/4885 |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | MMP1 914/4885MGAM 4301/4885GAA 367/4885 |
| US-20160215007-A1 | METHOD OF PRODUCING PYRAZINO[2,1-C][1,2,4]TRIAZINE COMPOUND | TYMP, DTYMK, MTAP | MMP1 3131/4885MGAM 2462/4885GAA 3489/4885 |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | MMP1 914/4885MGAM 4301/4885GAA 367/4885 |
| US-20110092459-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | COL1A1, PLOD3, THPO | MMP1 645/4885MGAM 4312/4885GAA 336/4885 |
| US-20110263607-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | COL1A1, HDGF, HCCS | MMP1 1200/4885MGAM 4301/4885GAA 338/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | MMP1 914/4885MGAM 4301/4885GAA 367/4885 |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | MMP1 1154/4885MGAM 3677/4885GAA 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.